Nuvectis Pharma has transformed from a single-drug oncology company into a rare-disease player by licensing worldwide rights (outside China) to NXP100, an oral therapy for paroxysmal nocturnal hemoglobinuria (PNH), and NXP200, an oncology asset, from Haisco Pharmaceutical Group. NXP100 showed strong Phase 3 results, outperforming the standard infused drug eculizumab with a 59.5% transfusion-free normal hemoglobin response versus 8.3%. Regulatory approval decisions in China are expected within 6 to 12 months, targeting late 2026 or early 2027. This move positions Nuvectis in a fast-growing market, with the global PNH treatment market projected to nearly double by 2030, and adds multiple near-term catalysts including upcoming oncology data and regulatory reviews.
Circle is launching its Arc blockchain public mainnet on September 16, transitioning from a private network to a live system backed by major financial institutions like BlackRock, Visa, and Mastercard. Valued at $3 billion from a $242 million presale...
Bitcoin's price experienced a volatile $3,215 intraday swing but settled around $77,300 with a modest 0.2% gain, reflecting a cautious market. The longer-term trend remains healthy, supported by strong moving averages, but short-term momentum is mixe...
Starbucks CEO Brian Niccol announced the company's turnaround is complete, citing improved customer experience and operational fixes like better staffing and store upgrades. The stock has surged nearly 30% since his hiring announcement, supported by ...
Bitcoin treasury companies do not always have stock valuations equal to the Bitcoin they hold. Their stock price can trade at a premium or discount to the Bitcoin value, reflecting investor expectations about how well management can grow Bitcoin hold...
XRP traded sideways around $1.42 after a volatile week that saw a 4% gain. Analysts highlight a long-term ascending triangle pattern with a key resistance at $3.66; a breakout above this could lead to a target near $60. Historical rallies suggest pot...
